A Dual-Targeting Ruthenium Nanodrug that Inhibits Primary Tumor Growth and Lung Metastasis by the PARP/ATM Pathway

Yu Lu, Di Zhu, Lin Gui, Yuanming Li, Wenjing Wang, Jiawang Liu, Yuji WangResearch 2020 · DOI

Abstract

Many studies have found that ruthenium complexes have unique biochemical characteristics and thus inhibit tumor growth or metastasis. Our aim was to report a novel dual-targeting ruthenium candidate 2b with both antitumor and antimetastatic functions that could target tumor sites using both EPR effects and TF/TFR. It was composed of ruthenium-complexed carboline acid and four chloride ions. In vitro, 2b could trigger DNA cleavage and thus block the cell cycle and cause apoptosis by the PARP/ATM pathway. In vivo, 2b could inhibit not only LLC tumor growth but also lung metastasis. We found apoptosis and decrease in CD31 expression in tumor tissue. In addition, we also found that 2b could collect in tumor tissue. Thus, we concluded that 2b could target tumors, inhibit tumor growth and prevent lung metastasis.

Introduction

One of the greatest hurdles in oncology is the "double-edged sword" of chemotherapy: drugs must be toxic enough to kill cancer cells but specific enough to leave healthy tissue alone. Furthermore, while many treatments can reduce the size of a primary tumor, they often fail to stop metastasis—the migration of cancer cells to distant organs like the lungs, which is the leading cause of cancer-related deaths. This study addresses these challenges by designing a ruthenium-complexed carboline acid (complex 2b) that uses both passive and active targeting to accumulate in tumors and trigger a specific molecular "self-destruct" sequence.

Methods and Characterization

The team synthesized complex 2b by combining ruthenium with carboline acid and four chloride ions. The resulting nanodrug was characterized using TEM and SEM to visualize physical structure, and UV/fluorescence spectroscopy to study interactions with DNA and human transferrin (hTF).

Figure 1: Chemical structures of the ligands and complex 2b, along with physical characterization via microscopy and binding affinity studies.

Biological assays were performed across several lung cancer cell lines, including LLC, 95D, and the paclitaxel-resistant A549-TAX. Western blotting was employed to track the expression of key proteins in the DNA-repair pathway, such as PARP, ATM, and Caspase 3.

Results and Discussion

Dual-Targeting and Efficacy

Complex 2b utilizes a synergistic targeting strategy. It leverages the Enhanced Permeability and Retention (EPR) effect to leak into tumor vasculature and active targeting by binding to Transferrin (TF), whose receptors are overexpressed in cancer cells. In vitro results showed significant dose-dependent inhibition of cell viability across all tested lines.

Figure 2: Cell viability assays across multiple lung cancer lines and Western blot analysis demonstrating the inhibition of the PARP/ATM DNA-repair pathway.

Molecular Mechanism: The PARP/ATM Trap

The drug induces DNA cleavage, which normally triggers repair mechanisms involving the ATM protein and PARP enzyme. Complex 2b interferes with this pathway, preventing repair and forcing the cell into apoptosis. This was confirmed by the upregulation of cleaved PARP and Caspase 3, alongside the downregulation of ATM and CDK1.

In Vivo Performance

In mouse models, 2b significantly reduced tumor volume and weight. Crucially, it suppressed lung metastasis, with treated mice showing a dramatic reduction in metastatic nodules in the lungs. Distribution studies confirmed that the highest concentrations of ruthenium accumulated in the tumor tissue, validating the dual-targeting design.

Conclusion

Complex 2b is a potent candidate for lung cancer therapy, offering a dual-targeting mechanism that effectively inhibits both primary tumor growth and metastasis. By disrupting the PARP/ATM DNA-repair pathway and reducing angiogenesis (evidenced by decreased CD31 expression), it provides a multi-faceted approach to cancer treatment. Future work will explore its long-term pharmacokinetics and potential in combination therapies.

Summary updated

Abstract

Abstract Many studies have found that ruthenium complexes have unique biochemical characteristics and thus inhibit tumor growth or metastasis. Our aim was to report a novel dual-targeting ruthenium candidate 2b with both antitumor and antimetastatic functions that could target tumor sites using both EPR effects and TF/TFR. It was composed of ruthenium-complexed carboline acid and four chloride ions. In vitro, 2b could trigger DNA cleavage and thus block the cell cycle and cause apoptosis by the PARP/ATM pathway. In vivo, 2b could inhibit not only LLC tumor growth but also lung metastasis. We found apoptosis and decrease in CD31 expression in tumor tissue. In addition, we also found that 2b could collect in tumor tissue. Thus, we concluded that 2b could target tumors, inhibit tumor growth and prevent lung metastasis.
BibTeX
@inproceedings{lu2020dual,
  author = {Yu Lu and Di Zhu and Lin Gui and Yuanming Li and Wenjing Wang and Jiawang Liu and Yuji Wang},
  title = {{A Dual-Targeting Ruthenium Nanodrug that Inhibits Primary Tumor Growth and Lung Metastasis by the PARP/ATM Pathway}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.3.rs-36952/v1},
}
Figure